$2.58T
Total marketcap
$168.73B
Total volume
BTC 50.03%     ETH 15.83%
Dominance

Intellia Therapeutics NTLA Stock

27.37 USD {{ price }} -3.286213% {{change_pct}}%
Exchange
NasdaqGM
Market Cap
2.63B USD
LOW - HIGH [24H]
27.08 - 28.05 USD
VOLUME [24H]
1.58M USD
{{ volume }}
P/E Ratio
0
Earnings per share
-5.42 USD

Intellia Therapeutics Price Chart

Intellia Therapeutics NTLA Financial and Trading Overview

Intellia Therapeutics stock price 27.37 USD
Previous Close 45.2 USD
Open 44.5 USD
Bid 0 USD x 1300
Ask 0 USD x 1000
Day's Range 44.38 - 45.68 USD
52 Week Range 32.44 - 76.45 USD
Volume 647.27K USD
Avg. Volume 999.73K USD
Market Cap 4.02B USD
Beta (5Y Monthly) 1.833098
PE Ratio (TTM) N/A
EPS (TTM) -5.42 USD
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 87.63 USD

NTLA Valuation Measures

Enterprise Value 3.21B USD
Trailing P/E N/A
Forward P/E -7.911458
PEG Ratio (5 yr expected) -0.28
Price/Sales (ttm) 75.11146
Price/Book (mrq) 3.3710608
Enterprise Value/Revenue 60.013
Enterprise Value/EBITDA -7.677

Trading Information

Intellia Therapeutics Stock Price History

Beta (5Y Monthly) 1.833098
52-Week Change 6.02%
S&P500 52-Week Change 20.43%
52 Week High 76.45 USD
52 Week Low 32.44 USD
50-Day Moving Average 40.42 USD
200-Day Moving Average 44.5 USD

NTLA Share Statistics

Avg. Volume (3 month) 999.73K USD
Avg. Daily Volume (10-Days) 996.45K USD
Shares Outstanding 88.14M
Float 83.5M
Short Ratio 4.85
% Held by Insiders 5.60%
% Held by Institutions 87.90%
Shares Short 5.24M
Short % of Float 6.72%
Short % of Shares Outstanding 5.94%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2022
Most Recent Quarter (mrq) March 31, 2023
Next Fiscal Year End December 31, 2023

Profitability

Profit Margin 0%
Operating Margin (ttm) -796.40%
Gross Margin 0%
EBITDA Margin 0%

Management Effectiveness

Return on Assets (ttm) -20.31%
Return on Equity (ttm) -40.14%

Income Statement

Revenue (ttm) 53.48M USD
Revenue Per Share (ttm) 0.67 USD
Quarterly Revenue Growth (yoy) 12.00%
Gross Profit (ttm) -367858000 USD
EBITDA -418008000 USD
Net Income Avi to Common (ttm) -430440000 USD
Diluted EPS (ttm) -5.32
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 933.54M USD
Total Cash Per Share (mrq) 10.59 USD
Total Debt (mrq) 126.13M USD
Total Debt/Equity (mrq) 10.59 USD
Current Ratio (mrq) 9.321
Book Value Per Share (mrq) 13.518

Cash Flow Statement

Operating Cash Flow (ttm) -362814016 USD
Levered Free Cash Flow (ttm) -213832496 USD

Profile of Intellia Therapeutics

Country United States
State MA
City Cambridge
Address 40 Erie Street
ZIP 02139
Phone 857 285 6200
Website https://www.intelliatx.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 598

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as for other product candidates, including NTLA-2003 for alpha-1 antitrypsin deficiency-liver disease; and NTLA-3001 for alpha-1 antitrypsin deficiency-lung disease; and NTLA-6001 for CD30+ lymphomas. It also focus on programs comprising hemophilia A and hemophilia B; ex vivo pipeline including NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Further, the company has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; and AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; and SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. Additionally, it has license and coloration agreement with Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. to develop optimally engineered natural killer cell therapies to cure patients with cancer; and Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Q&A For Intellia Therapeutics Stock

What is a current NTLA stock price?

Intellia Therapeutics NTLA stock price today per share is 27.37 USD.

How to purchase Intellia Therapeutics stock?

You can buy NTLA shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Intellia Therapeutics?

The stock symbol or ticker of Intellia Therapeutics is NTLA.

Which industry does the Intellia Therapeutics company belong to?

The Intellia Therapeutics industry is Biotechnology.

How many shares does Intellia Therapeutics have in circulation?

The max supply of Intellia Therapeutics shares is 96.11M.

What is Intellia Therapeutics Price to Earnings Ratio (PE Ratio)?

Intellia Therapeutics PE Ratio is now.

What was Intellia Therapeutics earnings per share over the trailing 12 months (TTM)?

Intellia Therapeutics EPS is -5.42 USD over the trailing 12 months.

Which sector does the Intellia Therapeutics company belong to?

The Intellia Therapeutics sector is Healthcare.

Intellia Therapeutics NTLA included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
{{ item.name }} {{ item.symbol }} {{ item.price }} {{ item.price_usd }}
{{ item.change_pct }}
{{ item.volume }} {{ item.volume_usd }} {{ item.low }} {{ item.low_usd }} {{ item.high }} {{ item.high_usd }} {{ item.components_count }} {{ item.volume }} {{ item.volume_usd }}
NASDAQ Composite IXIC 16103.45 USD
+0.82
4.52B USD 16094.17 USD 16247.59 USD 4.52B USD
NASDAQ DM Ex Japan Large Mid Ca NQDMXJPLMAUD 2100.38 AUD 1390.15 USD
<0.01
2100.38 AUD 1390.15 USD 2100.38 AUD 1390.15 USD
NASDAQ Biotechnology NBI 4337.34 USD
-0.65
4335.84 USD 4376.86 USD
NASDAQ HealthCare IXHC 986.88 USD
-0.25
986.44 USD 994.67 USD
NASDAQ Global Market Composite NQGM 2185.85 USD
-0.31
2177.48 USD 2204.21 USD
Stlmt ID NASDAQ Biotechnology NBX 4604.4 USD
-2.98
4555.41 USD 4917.8 USD